Journal of Drugs in Dermatology articles from April 2008

Journal of Drugs in Dermatology archives from April 2008

Antiaging and whole-body rejuvenation.(LETTER FROM THE GUEST EDITOR)(Brief article)
April 1, 2008... Aesthetic dermatology has continued to evolve over the last several years, driving major trends in development. Patients are looking for an improvement of their body parts on view, such as the face, decollete, hands, and legs. There has been a...

Letter to the editor.(Letter to the editor)
April 1, 2008... I am greatly appreciative of the fact that you printed an article by Campbell and Harmon entitled "Dermabrasion in Our Practice." I was fortunate to have benefited from the training and knowledge of some of the true masters of this procedure,...

Novel 3-in-1 wavelength light source for photorejuvenation.
April 1, 2008... Introduction Photorejuvenation involves the use of light or laser sources to reverse signs of photoaging and damage. Photodamage is the result of chronic ultraviolet (UV) light exposure which results in telangiectasias, pigmentary...

An evidence-based assessment of treatments for cellulite.
April 1, 2008... Introduction Cellulite is the characteristic, nonpathologic appearance of dimpled, "cottage cheese-like" skin surface change typically seen in women on the thighs and buttocks. It is also commonly seen on the abdomen, breasts, and arms....

Handheld LED array device in the treatment of acne vulgaris.
April 1, 2008... Introduction Acne is a chronic, inflammatory disease of the pilosebaceous units of the face, chest, and back. In the US, census data and prevalence reports indicate approximately 40 million adolescents and 25 million adults (85% of the...

Nonablative fractional resurfacing for total body rejuvenation.
April 1, 2008... Introduction Skin resurfacing with fractional photothermolysis is rapidly gaining acceptance for a variety of conditions including the treatment of rhytides, acne scars, facial and nonfacial photodamage, melasma, scars, and striae. There...

Evaluation of injectable CaHA for the treatment of mid-face volume loss.(Calcium hydroxylapatite)
April 1, 2008... Introduction Aging of the mid face is a complex process in which tissue atrophy and bone resorption, along with increased laxity of the skin, in combination create a hollowing, sagging, and the loss of the facial volume and contours...

Meta-analysis: griseofulvin efficacy in the treatment of tinea capitis.
April 1, 2008... Introduction Tinea capitis (TC) is a dermatophyte fungal infection of the scalp, hair follicles, and hair shafts. (1) It can affect all age groups but is most common among school children, and is particularly predominant in inner-city...

Psoriasis: cardiovascular risk factors and other disease comorbidities.
April 1, 2008... Introduction Psoriasis is a chronic, inflammatory skin disease for which several topical, systemic, and biological treatments are now available. (1-4) As a common immunologically-mediated skin disease, psoriasis reportedly occurs in up to...

Alefacept for erosive lichen planus: a case series.
April 1, 2008... Background Erosive lichen planus (LP) is a chronic inflammatory condition of the oral and vulvar mucosa often recalcitrant to therapy and can become severe. In its most severe forms, LP can cause significant morbidity including pain,...

Darier's disease: a commonly misdiagnosed cutaneous disorder.(CASE REPORTS)
April 1, 2008... Case Report A 48-year-old Caucasian woman presented to the emergency department complaining of a 2-week history of severe burning pain and pruritus in her chest, back, scalp, and lower extremities. The patient was taking diphenhydramine...

Erythroderma in a patient taking acitretin for plaque psoriasis.(CASE REPORTS)
April 1, 2008... Introduction Acitretin, a second generation systemic retinoid, has been approved for the treatment of severe recalcitrant psoriasis since 1997. (1) Aside from being a potent teratogen, the most common side effects are mucocutaneous,...

Acute generalized exanthematous pustulosis caused by terazosin hydrochloride.(CASE REPORTS)
April 1, 2008... Introduction Acute generalized exanthematous pustulosis (AGEP) is an uncommon cutaneous adverse drug reaction. Acute generalized exanthematous pustulosis is characterized by the sudden and simultaneous onset of a fever of more than...

Does the relative silicone content of different syringes affect the stability of foam in sclerotherapy?(CASE REPORTS)
April 1, 2008... Introduction Sclerotherapy has become the gold standard in the treatment of large and small varicose veins. The use of a foam technique is especially common in the treatment of veins greater than 1 mm in diameter. Foam has the advantage of...

The use of gabapentin for recurrent painful attacks with multiple piloleiomyomas.(CASE REPORTS)(Case study)
April 1, 2008... Case Report A 49-year-old man presented with a 35-year history of multiple, painful, reddish-brown papules confined to his back. The lesions first appeared during adolescence and had continued to increase in size and number (Figure 1). The...

Repairing DNA damage in xeroderma pigmentosum: T4N5 lotion and gene therapy.(NEWS, VIEWS, AND REVIEWS)(Brief article)
April 1, 2008... Abstract Patients with xeroderma pigmentosum (XP) have defective DNA repair and are at a high risk for cutaneous malignancies. Standard treatments for XP are limited in scope and effectiveness. Understanding the molecular etiology of XP...

A primer on topical antibiotics for the skin and eyes.(SCHOOLS OF PHARMACOLOGY)
April 1, 2008... Abstract A thorough knowledge of all topical antibiotics treatment options is important as more pathogens become resistant to standard therapies. As resistance to mupirocin increases, it seems that triple antibiotic ointments and...

Orphan drug designation for ADH-1.(PIPELINE PREVIEWS)(Adherex Technologies Inc.)(Brief article)
April 1, 2008... The FDA has granted orphan drug designation for ADH-1 from Adherex Technologies, Inc. The designation will allow ADH-1 to be used in combination therapy with melphalan for the treatment of stages IIB/C, III, and IV malignant melanoma. A phase...

Onset Therapeutics and genital warts.(PIPELINE PREVIEWS)(Brief article)
April 1, 2008... Onset Therapeutics has recently applied to the FDA for approval for a novel product to be used in the treatment of external genital warts. The active ingredient of this new product has not been disclosed. Onset plans to market this new product...

Vacuum Assisted Closure therapy in the treatment of diabetic foot ulcers.(PIPELINE PREVIEWS)(Brief article)
April 1, 2008... Kinetic Concepts, Inc recently announced positive results from a randomized, controlled, multicenter clinical trial on the efficacy of its Vacuum Assisted Closure[R] (V.A.C.[R]) System negative pressure wound therapy. The trial compared the...

GentleWaves LED Photomodulation System for periorbital wrinkles.(PIPELINE PREVIEWS)(Light BioScience L.L.C.)(Brief article)
April 1, 2008... The FDA has granted 510(k) over-the-counter clearance to Light BioScience, LLC for the sale and marketing of its photomodulation system, GentleWaves[R] LED Photomodulation[R] System. This device will be used in the treatment of periorbital...

Oncophage for metastatic melanoma.(PIPELINE PREVIEWS)
April 1, 2008... Antigenics, Inc recently announced the completion and publication of results from its phase 3 trial of Oncophage[R] (vitespen), a cancer vaccine, in the treatment of metastatic melanoma. The phase 3 study was an international, multicenter,...

Interleukin 12/23 monoclonal antibody in the treatment of psoriasis.(PIPELINE PREVIEWS)(Brief article)
April 1, 2008... A recent report indicates that ABT-874, a fully human interleukin 12/23 monoclonal antibody, is safe and efficacious in the treatment of moderate to severe chronic plaque psoriasis. The report details a randomized, double-blind,...

Onset Therapeutics and Anestafoam.(PIPELINE PREVIEWS)(Brief article)
April 1, 2008... Onset Therapeutics recently announced the marketing of Anestafoam[TM], a topical foam that contains lidocaine 4%. Anestafoam is the first and only formulation of lidocaine in a topical foam, and it incorporates Onset's Delevo[TM] Foam...

Centocor and ustekinumab.(PIPELINE PREVIEWS)(Centocor Inc.)(Brief article)
April 1, 2008... Centocor, Inc recently announced that its Biologics License Application (BLA) for ustekinumab (CNTO 1275) has been accepted for filing by the FDA for the treatment of chronic moderate to severe plaque psoriasis in adult patients. Ustekinumab is...

Study of benzoyl peroxide cream for mild to moderate acne vulgaris.(ACNE)(Brief article)
April 1, 2008... Sponsored by Northwestern University. The purpose of this study is to compare the efficacy of a benzoyl peroxide 2.5% cream formulation plus a moisturizing lotion versus benzoyl peroxide 2.5% cream alone for the treatment of acne vulgaris. ...

Efficacy and safety of azithromycin SR compared with minocycline in acne.(ACNE)
April 1, 2008... Sponsored by Pfizer. The primary objective is to evaluate the clinical efficacy of azithromycin microspheres treatment in outpatients with moderate to severe inflammatory acne compared with first-line treatment minocycline after 8 weeks of...

Photodynamic therapy (PDT) with methyl aminolevulinate (MAL) cream in moderate to severe acne.(ACNE)(Brief article)
April 1, 2008... Sponsored by PhotoCure. This multicenter study will be divided into 2 phases. The first phase will be an open-label, dose-escalation phase, while the second will be a blinded, randomized, vehicle-controlled, parallel-group, dose-response phase....

Treatment of alopecia areata of the scalp with intradermal injections of botulinum toxin.(ALOPECIA)(Brief article)
April 1, 2008... Sponsored by the University of British Columbia. The purpose of this study is to examine prospectively the safety and efficacy of botulinum toxin A (Botox[R]) injections in the treatment of patients with alopecia areata of the scalp. ...

A study to assess the efficacy and safety of dutasteride 0.5 mg once daily for 6 months in the treatment of male subjects with androgenetic alopecia.(ALOPECIA)
April 1, 2008... Sponsored by GlaxoSmithKline. The aim of this Phase 3 study is to compare the efficacy, safety and tolerability of dutasteride (0.5 mg) with a placebo for 6 months in Korean male subjects with androgenetic alopecia in the vertex region (types...

Efficacy of therapy with the spironolactone pills compared to minoxidil lotion in female pattern hair loss.(ALOPECIA)(Brief article)
April 1, 2008... Sponsored by the University of British Columbia. This study evaluates the efficacy of therapy with the anti-androgen spironolactone compared to topical minoxidil in female pattern hair loss. Condition Intervention ...

Efficacy study of montelukast in atopic dermatitis induced by food allergens.(ATOPIC DERMATITIS)(Brief article)
April 1, 2008... Sponsors and Collaborators: 1st Allergy & Clinical Research Center; Merck. Atopic dermatitis (AD) is a disease found in children; the focus of the study is the mechanisms associated in children with AD induced by food allergies. Condition...

The effects of probiotics in atopic dermatitis.(ATOPIC DERMATITIS)(Brief article)
April 1, 2008... Sponsors and Collaborators: University of California, Los Angeles; Thrasher Research Fund. The purpose of this study is to study the clinical effects of taking probiotics in patients who have moderate to severe atopic dermatitis. ...

A study of the safety and efficacy of JNJ-26113100 in the treatment of adult atopic dermatitis.(ATOPIC DERMATITIS)(Brief article)
April 1, 2008... Sponsored by Alza Corporation. The purpose of this study is to evaluate the safety and effectiveness of oral administration of 4 dose regimens of JNJ-26113100 prepared in a capsule formulation administered for 6 weeks in the treatment of adult...

Novel topical treatment of hand dermatitis (eczema).(ATOPIC DERMATITIS)(Brief article)
April 1, 2008... Sponsors and Collaborators: Biomedical Development Corporation; National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS). This study is designed as a prospective, randomized, double-blind right/left comparison of Epikeia[R]...

Imiquimod in children with plaque morphea.(CONNECTIVE TISSUE DISORDERS)(Brief article)
April 1, 2008... Sponsored by The Hospital for Sick Children. This is a pilot study designed to assess the potential efficacy and relative safety of imiquimod in children with plaque morphea. Condition Intervention Phase Scleroderma,...

UVA1 light for treatment of scleroderma and similar conditions.(CONNECTIVE TISSUE DISORDERS)(Brief article)
April 1, 2008... Sponsored by the University of Michigan. The purpose of this investigation is to evaluate the effectiveness of an investigational device which is similar in appearance to a "tanning bed" but which emits ultraviolet irradiation of a specific...

Clobetasol versus pimecrolimus for vulvar lichen sclerosus.(CONNECTIVE TISSUE DISORDERS)
April 1, 2008... Sponsors and Collaborators: Center for Vulvovaginal Disorders; Novartis. This study is designed to compare the effectiveness and safety of a topical corticosteroid (clobetasol) versus Elidel[R] 1% cream for the treatment of lichen sclerosus....

A study to evaluate psoriasis outcomes and safety events in patients with chronic moderate to severe plaque psoriasis (response).(PSORIASIS)
April 1, 2008... Sponsored by Genentech. This is a multicenter, prospective, 5-year surveillance study of approximately 5000 Raptiva[R]-treated patients and approximately 500 non-Raptiva treated patients (formerly 2500 comparison patients who were treated with...

Effects of TNF-alpha antagonism (etanercept) in patients with the metabolic syndrome and psoriasis.(PSORIASIS)(Brief article)
April 1, 2008... Sponsors and Collaborators: Massachusetts General Hospital; Amgen. The purpose of this study is to determine how substances produced in the fat (inflammatory markers) relate to the risk of heart disease in people with the metabolic syndrome and...

Study of tumor necrosis factor receptor fusion protein etanercept (Enbrel) in psoriasis of the hands and/or feet.(PSORIASIS)(Brief article)
April 1, 2008... Sponsors and Collaborators: University of California, Irvine; Amgen. The purpose of this research study is to see how well (compared to placebo) Enbrel[R] (etanercept) 50 mg twice a week affects plaque psoriasis of the hands and/or feet...

Psunrise: prospective study using remicade in psoriasis patients with an inadequate response to etanercept.(PSORIASIS)(Brief article)
April 1, 2008... Sponsored by Centocor Inc. The purpose of this study is to test the safety and effectiveness of infliximab in patients with plaque psoriasis who have been receiving the drug etanercept for treatment of their plaque psoriasis for at least 4...

Adalimumab in combination with topical treatment (calcipotriol/betamethasone) in subjects with moderate to severe psoriasis and insufficient response to classic systemic treatment (believe).(PSORIASIS)(Brief article)
April 1, 2008... Sponsored by Abbott. The objective of this study is to assess the efficacy and safety of adalimumab in combination with a topical psoriasis treatment (calcipotriol/betamethasone) versus adalimumab in combination with matching vehicle in...

Optical imaging of skin cancers for margin delineation of non-melanoma skin cancers.(SKIN CANCER)(Brief article)
April 1, 2008... Sponsors and Collaborators: MD Anderson Cancer Center; National Institute of Dental and Craniofacial Research (NIDCR). The primary objective of this exploratory laboratory study is to evaluate the ability of optical imaging technologies such as...

Photodynamic therapy using silicon phthalocyanine 4 in treating patients with actinic keratosis, Bowen's disease, skin cancer, or stage I or stage II mycosis fungoides.(SKIN CANCER)(Brief article)
April 1, 2008... Sponsors and Collaborators: Case Comprehensive Cancer Center; National Cancer Institute (NCI). This phase 1 trial is studying the side effects and best dose of photodynamic therapy using silicon phthalocyanine 4 in treating patients with...

Tumorapa 1: efficacy of rapamycin in secondary prevention of skin cancers in kidney transplant recipients.(SKIN CANCER)(Brief article)
April 1, 2008... Sponsored by Hospices Civils de Lyon. The aim of the study is to assess the incidence of subsequent skin cancers over 2 years in patients who are switched to rapamycin as compared to patients who are maintained under calcineurin inhibitors. ...